Get the Stockscreener App
0.6223
1.34%
0.0082
After Hours:
.61
-0.0123
-1.98%
Context Therapeutics Inc stock is traded at $0.6223, with a volume of 1.73M.
It is up +1.34% in the last 24 hours and up +7.29% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.6141
Open:
$0.6132
24h Volume:
1.73M
Relative Volume:
0.77
Market Cap:
$57.18M
Revenue:
-
Net Income/Loss:
$-40.23M
P/E Ratio:
-1.4557
EPS:
-0.4275
Net Cash Flow:
$-34.82M
1W Performance:
+1.02%
1M Performance:
+7.29%
6M Performance:
-71.58%
1Y Performance:
-26.00%
1-Day Range:
$0.6018
$0.65
1-Week Range:
$0.5602
$0.65
52-Week Range:
$0.5451
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6223 | 56.42M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
CNTX|Context Therapeutics Inc|Price:0.620|Chg%:+0.006 - TradingKey
BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX) - Stock Titan
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – SWB:6K9 - TradingView
Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX - TradingView
SRNE stock holds on Sorrento Therapeutics identity and filing context - ad-hoc-news.de
Enterprise value to revenue forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Grants 146,000-Share Option to New Employee - MyChesCo
Context Therapeutics Q1 2026 Earnings: EPS Beat by 24.81% Offset by Stock Decline Amid Pre-Revenue Stage - dars.gov.et
Context Therapeutics (CNTX) Proxy filing Summary - Quartr
Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary - Quartr
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Context Therapeutics hire receives 146,000-share stock option at $0.70 - Stock Titan
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst - TipRanks
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes - 富途牛牛
Context Therapeutics (CNTX) Surges Nearly 10% as Momentum BuildsSafe Entry Stocks - dars.gov.et
Context Therapeutics Joins Russell 2000, Russell 3000 Indexes - Moomoo
Context Therapeutics stock rises on Russell index inclusion By Investing.com - Investing.com Nigeria
Context Therapeutics stock rises on Russell index inclusion - Investing.com
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
Context Therapeutics (CNTX) Gains 7.46% as Stock Tests Key Resistance at $0.68Social Sentiment - dars.gov.et
Context Therapeutics Inc. (CNTX) Rallies Over 7% on Elevated Volume, Approaching Key ResistanceBPI Bull Correction - dars.gov.et
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Enterprise value to revenue forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Index - marketscreener.com
Context Therapeutics Shareholders Approve Stock Increase and Directors - The Globe and Mail
Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director Linda West awarded 45K stock options - Stock Titan
Director at Context Therapeutics (CNTX) receives 45,000 stock options award - Stock Titan
Director Philip Kantoff receives 45,000 CNTX stock options at $0.576 exercise price - Stock Titan
Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M - Stock Titan
Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX) - TradingView
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):